Published in
Elsevier, Annals of Oncology, (28), p. iii140, 2017
DOI: 10.1093/annonc/mdx262.008
Links
Tools
Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Journal article published in 2017 by
Jordi Bruix 
,
Philippe Merle,
Alessandro Granito,
Yi-Hsiang Huang,
Gyorgy Bodoky,
Osamu Yokosuka,
Olivier Rosmorduc,
Valeriy Breder,
Rene Gerolami,
Gianluca Masi,
Paul J. Ross,
Shukui Qin,
Tianqiang Song,
Jean-Pierre Bronowicki,
Isabelle Ollivier-Hourmand
and other authors.
,
Philippe Merle,
Alessandro Granito,
Yi-Hsiang Huang,
Gyorgy Bodoky,
Osamu Yokosuka,
Olivier Rosmorduc,
Valeriy Breder,
Rene Gerolami,
Gianluca Masi,
Paul J. Ross,
Shukui Qin,
Tianqiang Song,
Jean-Pierre Bronowicki,
Isabelle Ollivier-Hourmand
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 